Fig. 5: Emapalumab does not affect CAR.CD19-T cell anti-lymphoma activity in NSG mouse model.
a Schematic representation of the first experimental setting: mice (n = 4 in each cohort) were infused with 0.25 × 106 FF-LUC Daudi cells/mouse at Day-2 and treated with 10 × 106 effector T (NT or CAR.CD19) cells/mouse at Day 0. At Day 7, 11 15 mice received 100 mg/kg emapalumab and were evaluated for lymphoma eradication. b Bioluminescence imaging of each treatment cohort. c Mean ± SD of bioluminescence values of the four mice cohorts over time, receiving only tumor (black dotted line), NT (gray line), CAR.CD19-T cells in the absence of emapalumab (black line) or CAR.CD19-T cells in the presence of emapalumab (red line). d Mean ± SD of bioluminescence values of the four mice cohorts at Day 28. Data were compared by a two-tailed Student t-test and p value <0.05 was considered statistically significant. e Schematic representation of the second experimental setting: mice (n = 4 in each cohort) were infused with 0.25 × 106 FF-LUC Daudi cells/mouse at Day-8 and treated with 10 × 106 effector T (NT or CAR.CD19) cells/mouse at Day 0. At Day 0, 3, 6 mice received 100 mg/kg emapalumab and evaluated for lymphoma eradication. f Bioluminescence imaging of each treatment cohort. g Bioluminescence values of each mouse, receiving NT cells in the absence of emapalumab (red line) or in the presence of emapalumab (red dotted line) or CAR.CD19-T cells in the absence of emapalumab (black line) or CAR.CD19-T cells in the presence of emapalumab (black dotted line). h Mean ± SD of bioluminescence values of the four mice cohorts at Day 15. Data were compared by a two-tailed Student t-test and p value <0.05 was considered statistically significant. Student’s t-test was employed to calculate statistically significant differences between groups. Source data are provided as a Source Data file.
